30 August 2008

Contents

Editorial

• Volume 9 Number 7/8 Jul/Aug 2008

Conference reports

• XVII International HIV Resistance Workshop (IHDRW), 6-10 June 2008, Sitges

• Integrase inhibitor resistance and cross-resistance: weighing viral fitness and the option to benefit from second-generation compounds

• Understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs

• Pipeline antiretrovirals: IDX899, CHX157 and bevirimat

• Lack of virological impact of treatment intensification in suppressed patients supports latent viral reservoir as source of residual viraemia

• NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection

• Detecting viral tropism: impact of a more sensitive Trofile (ES) assay

• Low frequency K103N mutations are associated with poor virological response to NNRTI based therapy

• 14th Annual BHIVA Conference, 23-25 April 2008, Belfast

• Bone problems raised in several UK studies

• Late diagnosis in adolescence of vertically acquired HIV infection

• Case study of multi-drug resistant woman receiving newer antiretroviral drugs in pregnancy

• Predictors of treatment failure in Western Cape, South Africa

• Late pregnancy loss in HIV-positive women

• Renal tubular dysfunction with tenofovir-based HAART in four vertically infected adolescents

• 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008

• The unmet need for contraception services for women receiving ART

• Valacyclovir decreases plasma and genital viral loads in HSV-2/HIV-1 co-infected women

• HPV genotypes in HIV-positive women in Zimbabwe and Uganda

Antiretrovirals

• Boosted atazanavir approved in Europe as first-line therapy

• BMS and Merck discontinue 100mg capsule formulation of efavirenz used for paediatric treatment

• Saquinavir (Invirase) interactions with digoxin, garlic capsules, methadone, tipranavir and omeprazole: US label changes

• US label changes for nevirapine paediatric solution

• New US pediatric dosing for lopinavir/r

• New US pediatric dosing for tipranavir/r

• DSMB stops ACTG study due to suboptimal responses

Treatment access

• FDA approval of generic ARVs

• Access to generic efavirenz in South Africa: MSD agrees to grant licenses on reasonable terms

• Reaching 3 by 5…by 7: new report on universal access

• Oxfam criticises DFID’s new strategy as a “missed opportunity”